全文获取类型
收费全文 | 426篇 |
免费 | 40篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 19篇 |
妇产科学 | 9篇 |
基础医学 | 56篇 |
口腔科学 | 4篇 |
临床医学 | 82篇 |
内科学 | 96篇 |
皮肤病学 | 14篇 |
神经病学 | 20篇 |
特种医学 | 20篇 |
外国民族医学 | 1篇 |
外科学 | 23篇 |
综合类 | 10篇 |
现状与发展 | 1篇 |
预防医学 | 53篇 |
眼科学 | 7篇 |
药学 | 32篇 |
中国医学 | 1篇 |
肿瘤学 | 18篇 |
出版年
2023年 | 4篇 |
2022年 | 10篇 |
2021年 | 26篇 |
2020年 | 11篇 |
2019年 | 20篇 |
2018年 | 14篇 |
2017年 | 11篇 |
2016年 | 14篇 |
2015年 | 15篇 |
2014年 | 19篇 |
2013年 | 17篇 |
2012年 | 15篇 |
2011年 | 28篇 |
2010年 | 27篇 |
2009年 | 12篇 |
2008年 | 16篇 |
2007年 | 25篇 |
2006年 | 19篇 |
2005年 | 22篇 |
2004年 | 12篇 |
2003年 | 17篇 |
2002年 | 8篇 |
2001年 | 11篇 |
2000年 | 4篇 |
1999年 | 7篇 |
1998年 | 11篇 |
1997年 | 9篇 |
1996年 | 4篇 |
1995年 | 2篇 |
1994年 | 3篇 |
1992年 | 2篇 |
1991年 | 2篇 |
1990年 | 4篇 |
1988年 | 4篇 |
1987年 | 3篇 |
1986年 | 1篇 |
1985年 | 4篇 |
1984年 | 7篇 |
1983年 | 5篇 |
1982年 | 2篇 |
1981年 | 3篇 |
1980年 | 3篇 |
1979年 | 3篇 |
1978年 | 1篇 |
1977年 | 1篇 |
1975年 | 1篇 |
1959年 | 2篇 |
1941年 | 2篇 |
1939年 | 1篇 |
1936年 | 1篇 |
排序方式: 共有468条查询结果,搜索用时 15 毫秒
11.
Altered spectra of hypermutation in antibodies from mice deficient for the DNA mismatch repair protein PMS2 总被引:12,自引:0,他引:12 下载免费PDF全文
David B. Winter Quy H. Phung Asad Umar Sean M. Baker Robert E. Tarone Kiyoji Tanaka R. Michael Liskay Thomas A. Kunkel Vilhelm A. Bohr Patricia J. Gearhart 《Proceedings of the National Academy of Sciences of the United States of America》1998,95(12):6953-6958
Mutations are introduced into rearranged Ig variable genes at a frequency of 10−2 mutations per base pair by an unknown mechanism. Assuming that DNA repair pathways generate or remove mutations, the frequency and pattern of mutation will be different in variable genes from mice defective in repair. Therefore, hypermutation was studied in mice deficient for either the DNA nucleotide excision repair gene Xpa or the mismatch repair gene Pms2. High levels of mutation were found in variable genes from XPA-deficient and PMS2-deficient mice, indicating that neither nucleotide excision repair nor mismatch repair pathways generate hypermutation. However, variable genes from PMS2-deficient mice had significantly more adjacent base substitutions than genes from wild-type or XPA-deficient mice. By using a biochemical assay, we confirmed that tandem mispairs were repaired by wild-type cells but not by Pms2−/− human or murine cells. The data indicate that tandem substitutions are produced by the hypermutation mechanism and then processed by a PMS2-dependent pathway. 相似文献
12.
Background:
Mormordica charantia (bitter melon) has been investigated for lowering plasma glucose in patients with diabetes mellitus (DM). Previous data has offered inconclusive and inconsistent results about the benefits of bitter melon in patients with DM. Our current project aims to determine whether bitter melon has a favorable effect in lowering plasma glucose in patients with DM.Methods:
We searched PubMed, EMBASE and the Cochrane Library from inception to July 2013 without any language restrictions for randomized controlled trials (RCTs) evaluating bitter melon to no treatment in patients with type 1 or type 2 diabetes. Study selection, data extraction and validity of each article were independently assessed by two investigators. Articles were appraised for proper random sequence generation, allocation concealment, blinding, selective reporting and completeness of outcomes reporting to assess the risk for biases. The glycemic results of each RCT were analyzed to yield weighted mean differences (WMDs) and 95% confidence intervals (CIs).Results:
A total of four RCTs, each with 40–66 participants, followed between 4 and 12 weeks were identified in this meta-analysis. Overall risk of bias for each article included was determined to be unclear. In total, 208 participants with type 2 DM (mean age of 56.5 years) were evaluated. Compared with no treatment, bitter melon did not significantly lower A1C (WMD −0.13%, 95% CI −0.41 to 0.16) nor fasting plasma glucose (FPG) 47 (WMD 2.23 mg dl−1, 95% CI −14.91 to 19.37).Conclusions:
Bitter melon supplementation compared with no treatment did not show significant glycemic improvements on either A1c or FPG. 相似文献13.
Ma X Helgason E Phung QT Quan CL Iyer RS Lee MW Bowman KK Starovasnik MA Dueber EC 《Proceedings of the National Academy of Sciences of the United States of America》2012,109(24):9378-9383
Tank-binding kinase (TBK)1 plays a central role in innate immunity: it serves as an integrator of multiple signals induced by receptor-mediated pathogen detection and as a modulator of IFN levels. Efforts to better understand the biology of this key immunological factor have intensified recently as growing evidence implicates aberrant TBK1 activity in a variety of autoimmune diseases and cancers. Nevertheless, key molecular details of TBK1 regulation and substrate selection remain unanswered. Here, structures of phosphorylated and unphosphorylated human TBK1 kinase and ubiquitin-like domains, combined with biochemical studies, indicate a molecular mechanism of activation via transautophosphorylation. These TBK1 structures are consistent with the tripartite architecture observed recently for the related kinase IKKβ, but domain contributions toward target recognition appear to differ for the two enzymes. In particular, both TBK1 autoactivation and substrate specificity are likely driven by signal-dependent colocalization events. 相似文献
14.
15.
López-Labrador FX Dove L Hui CK Phung Y Kim M Berenguer M Wright TL 《Virus research》2007,130(1-2):285-291
Chronic infection by Hepatitis C Virus (HCV) causes liver fibrosis, which is accelerated by unknown mechanisms in patients with HIV-1 coinfection. The evolution of HCV quasispecies in this setting of coinfection is not fully understood. To compare HCV quasispecies between HIV–HCV coinfection and HCV monoinfection, we sequenced 340 HCV clones from the HVR-1 and NS3 regions at two different time points in two groups of treatment-naïve patients with HCV-1a infection: (1) HIV–HCV positive (n = 6); and (2) HIV negative–HCV positive (n = 3). In HCV/HIV coinfection, we found a trend for reduced HCV genetic complexity and diversity, and a trend towards reduced dN/dS ratios in the HVR-1 region, especially in those patients with CD4 < 200 cells/mm3, who lost positive selective immune pressure in the HVR-1 region. Differences in immune regulation of HCV quasispecies in HIV coinfected individuals deserve further exploration to clarify the different outcomes of chronic hepatitis C noted between the immunocompromised and the immunocompetent host. 相似文献
16.
Ha-Soon Choi Paul V. Rucker Zhicheng Wang Yi Fan Pamela Albaugh Greg Chopiuk Francois Gessier Fangxian Sun Francisco Adrian Guoxun Liu Tami Hood Nanxin Li Yong Jia Jianwei Che Susan McCormack Allen Li Jie Li Auzon Steffy AnneMarie Culazzo Celine Tompkins Van Phung Andreas Kreusch Min Lu Bin Hu Apurva Chaudhary Mahavir Prashad Tove Tuntland Bo Liu Jennifer Harris H. Martin Seidel Jon Loren Valentina Molteni 《ACS medicinal chemistry letters》2015,6(5):562-567
17.
Brett Scholz Sarah Gordon Julia Bocking Jackie Liggins Peter Ellis Cath Roper Chris Platania‐Phung Brenda Happell 《International journal of mental health nursing》2019,28(4):899-908
Non‐consumer researchers collaborating with consumer researchers can benefit from greater relevance of research and improved congruence between research processes and health policy. As with all research collaborations, such partnerships are both constrained and facilitated by research ecosystems. However, it seems that collaborations with consumer researchers are impacted in particular ways by the research ecosystem. Drawing on ecological systems theory, this study aims to improve understandings of how ecological structures impact collaborations between non‐consumer and consumer researchers. Interviews were conducted with 11 non‐consumer researchers from a range of mental health disciplines about their experiences collaborating with consumer researchers. One theme developed through analysis of the data set related to the research ecosystem. Data from this theme were extracted and discursively analysed using the principles of discursive psychology. Findings emphasize distinct factors that influence collaborations at each level of the ecosystem, encompassing both local research culture and broader research systems. Findings suggest that external pressures (such as deadlines for funding applications, or bureaucratic processes) from the broader ecosystemic levels need to be challenged at the local collaboration level. Non‐consumer researchers might support collaborations through, for instance, working to create enhanced flexibility in research timelines, or making time for relationship building, thus fostering more meaningful collaborations. 相似文献
18.
19.
Spatiotemporal Trend Analysis of Precipitation Extremes in Ho Chi Minh City,Vietnam During 1980-2017
Nguyen Trong Quan Dao Nguyen Khoi Nguyen Xuan Hoan Nguyen Ky Phung Thanh Duc Dang 《国际灾害风险科学学报(英文版)》2021,12(1):131-146
In this study,the spatiotemporal variability of trends in extreme precipitation events in Ho Chi Minh City during the period 1980-2017 was analyzed based on sev... 相似文献
20.
Nguyen Minh Tam Minh Quan Pham Nguyen Xuan Ha Pham Cam Nam Huong Thi Thu Phung 《RSC advances》2021,11(28):17478
The coronavirus disease (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread worldwide recently, leading to global social and economic disruption. Although the emergently approved vaccine programs against SARS-CoV-2 have been rolled out globally, the number of COVID-19 daily cases and deaths has remained significantly high. Here, we attempt to computationally screen for possible medications for COVID-19 via rapidly estimating the highly potential inhibitors from an FDA-approved drug database against the main protease (Mpro) of SARS-CoV-2. The approach combined molecular docking and fast pulling of ligand (FPL) simulations that were demonstrated to be accurate and suitable for quick prediction of SARS-CoV-2 Mpro inhibitors. The results suggested that twenty-seven compounds were capable of strongly associating with SARS-CoV-2 Mpro. Among them, the seven top leads are daclatasvir, teniposide, etoposide, levoleucovorin, naldemedine, cabozantinib, and irinotecan. The potential application of these drugs in COVID-19 therapy has thus been discussed.Approved drugs predicted to interact with critical residues in the substrate-binding site of SARS-CoV-2 Mpro can be promising inhibitors. 相似文献